1. Home
  2. USLM vs NAMS Comparison

USLM vs NAMS Comparison

Compare USLM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USLM

United States Lime & Minerals Inc.

HOLD

Current Price

$110.17

Market Cap

3.1B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$28.50

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USLM
NAMS
Founded
1948
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.3B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
USLM
NAMS
Price
$110.17
$28.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$138.00
$46.75
AVG Volume (30 Days)
113.8K
838.8K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
0.19%
N/A
EPS Growth
23.22
N/A
EPS
1.06
N/A
Revenue
$144,435,000.00
N/A
Revenue This Year
$27.25
$17.96
Revenue Next Year
$13.76
$540.65
P/E Ratio
$23.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$94.41
$16.79
52 Week High
$141.44
$42.00

Technical Indicators

Market Signals
Indicator
USLM
NAMS
Relative Strength Index (RSI) 31.94 36.61
Support Level $94.77 $23.48
Resistance Level $129.37 $37.25
Average True Range (ATR) 6.09 1.69
MACD -3.19 -0.61
Stochastic Oscillator 19.80 7.88

Price Performance

Historical Comparison
USLM
NAMS

About USLM United States Lime & Minerals Inc.

United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: